| __timestamp | Halozyme Therapeutics, Inc. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 35942000 | 5078000000 |
| Thursday, January 1, 2015 | 40028000 | 4717000000 |
| Friday, January 1, 2016 | 45853000 | 5096000000 |
| Sunday, January 1, 2017 | 53816000 | 4986000000 |
| Monday, January 1, 2018 | 60804000 | 4214000000 |
| Tuesday, January 1, 2019 | 77252000 | 3806000000 |
| Wednesday, January 1, 2020 | 45736000 | 3671000000 |
| Friday, January 1, 2021 | 50323000 | 3528000000 |
| Saturday, January 1, 2022 | 143526000 | 3445000000 |
| Sunday, January 1, 2023 | 149182000 | 3498000000 |
| Monday, January 1, 2024 | 3702000000 |
In pursuit of knowledge
In the competitive pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Teva Pharmaceutical Industries Limited and Halozyme Therapeutics, Inc. have taken different paths in optimizing these costs.
From 2014 to 2023, Teva's SG&A expenses have decreased by approximately 31%, from $5.08 billion to $3.50 billion. This reduction reflects a strategic shift towards cost efficiency. In contrast, Halozyme's SG&A expenses have surged by over 300%, from $35.9 million to $149.2 million, indicating significant investment in growth and expansion.
Teva's cost-cutting measures may enhance short-term profitability, but Halozyme's increased spending could drive long-term growth. Investors should consider these strategies when evaluating potential returns. As the industry evolves, the ability to balance cost management with growth investment will be key to success.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Teva Pharmaceutical Industries Limited
Comparing SG&A Expenses: Zoetis Inc. vs Teva Pharmaceutical Industries Limited Trends and Insights
Cost of Revenue: Key Insights for Teva Pharmaceutical Industries Limited and Halozyme Therapeutics, Inc.
Breaking Down SG&A Expenses: Teva Pharmaceutical Industries Limited vs Catalent, Inc.
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs BioMarin Pharmaceutical Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Teva Pharmaceutical Industries Limited and Opthea Limited
Teva Pharmaceutical Industries Limited or Alkermes plc: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Perrigo Company plc
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Amphastar Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs Pharming Group N.V.
Comparing SG&A Expenses: Halozyme Therapeutics, Inc. vs Protagonist Therapeutics, Inc. Trends and Insights
Halozyme Therapeutics, Inc. and Xencor, Inc.: SG&A Spending Patterns Compared